Tevogen Bio Stock Price, News & Analysis

Tevogen Bio (TVGN) has signed an agreement with CD 8 Technology Services for developing a turn-key facility supporting in-house pre-clinical research and GMP cell therapy production capabilities. The agreement has an initial 12-month term with automatic renewal.

The facility will be primarily staffed and operated by Tevogen Bio, marking a strategic move to accelerate development timelines, maintain operational agility, and control costs. The company expects this agreement to help overcome typical capital barriers in building GMP capabilities at scale.

The agreement formalizes a previously announced letter of intent with CD8, a company associated with Dr. Manmohan Patel, who owns over 5% of Tevogen's common stock. Specific details including scope of work, costs, and timelines will be outlined in future work orders.

Tevogen Bio (TVGN) has commissioned Databricks to accelerate the development of PredicTcell, their proprietary AI-driven target prediction model for precision immunotherapy. The collaboration will leverage Databricks' expertise in data engineering and AI systems to enhance PredicTcell's capabilities in modeling immunologically active HLA+ peptide complexes and TCR engagement prediction.

The partnership focuses on developing two foundational models based on Tevogen's ExacTcell™ platform: predicting immunologically active peptides through machine learning and creating a predictive T cell receptor binding model. This marks the third pillar of Tevogen.AI, alongside Microsoft Research providing digital infrastructure and AI expertise, while Tevogen Bio leads clinical and immunological science strategy.

Tevogen Bio Holdings (Nasdaq: TVGN) announces CEO Dr. Ryan Saadi's participation in BioNJ's Fifteenth Annual Bio Partnering Conference on May 13, 2025, at The Liberty Science Center in Jersey City. Dr. Saadi will join a panel discussion titled 'Paths to Liquidity: Strategies for Adapting to a Volatile Market,' alongside executives from J.P. Morgan, RSM, and Cantor Fitzgerald.

The conference aims to connect investors, BD professionals, academic collaborators, and biopharmaceutical industry executives to promote strategic partnerships, funding opportunities, and healthcare innovation. The event features 1:1 partnering sessions, company pitch presentations, Industry Connections Desk, exhibits, and networking opportunities.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced the launch of Tevogen Generics, a new initiative aimed at domestic manufacturing of unbranded pharmaceuticals and APIs. This effort aligns with President Trump's recent tariff-related statements and national focus on pharmaceutical affordability.

The company has appointed Sadiq Khan, MBA, the current Chief Commercial Officer, as Interim Head of this new venture. Tevogen Generics becomes the company's third strategic pillar, alongside:

• Tevogen Bio - specialty immunotherapy biotech focusing on off-the-shelf, precision T cell therapies
• Tevogen.AI - utilizing artificial intelligence for drug discovery and healthcare delivery optimization
• Tevogen Generics - focused on making essential medicines accessible

Tevogen Bio Holdings (Nasdaq: TVGN) participated in the AI x Bio Philly event, showcasing the intersection of artificial intelligence and life sciences in Philadelphia. Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, presented alongside leaders from BioCurie, BioPhy AI, and Proscia during the AI Demos and Presentations session.

Mehta's presentation highlighted Tevogen.AI's proprietary AI technology, which aims to accelerate the development of off-the-shelf precision T cell therapies through computational modeling of T cell receptor (TCR) engagement with immunologically active HLA+ peptide complexes. The event was hosted by BioBuzz, BitsInBio, Atria, and Zetta, bringing together innovators, entrepreneurs, and investors in the biotechnology sector.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced that company insiders, including executive officers and board members, currently hold approximately 74% of outstanding shares as of April 7, 2025. This significant insider ownership demonstrates management's confidence in the company's progress and potential.

The healthcare company operates in two main areas: immunotherapy through Tevogen Bio, which develops off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers, and artificial intelligence through Tevogen.AI, focused on enhancing drug discovery, clinical trial efficiency, and patient access. The company operates solely in the U.S. and maintains a tariff-insensitive position amid current market volatility.

CEO Dr. Ryan Saadi highlighted that insiders have only sold shares to satisfy tax obligations related to restricted stock vesting, further emphasizing their commitment to the company's mission of redefining the future of medicine.

Tevogen Bio (Nasdaq: TVGN) announced two key developments: First, CEO Ryan Saadi has been named to the 2025 Health Care Power List by NJBIZ, recognizing his leadership in healthcare innovation. Second, the company appointed David E. Banko as Global Head of Government Affairs and Patient Access, who will focus on advancing patient access and securing coding, coverage, and reimbursement pathways.

The company reaffirmed its previously announced topline forecast of $1 billion in launch year for Tevogen Bio Oncology and nearly $1 billion for Tevogen Bio Specialty Care. These developments align with the company's commercialization strategy as it continues to advance its AI-driven immunotherapy drug discovery platform.

Tevogen Bio (Nasdaq: TVGN) has appointed David E. Banko, CPA as Global Head of Government Affairs and Patient Access to advance its commercialization strategy. Banko brings over 30 years of experience in market access and health policy across pharma, medical devices, diagnostics, and hospital finance.

In his new role, Banko will lead market access strategies for Tevogen's product portfolio in oncology, virology, neurology, and rheumatology. His responsibilities include:

• Advancing patient access to therapies under development
• Engaging with government and private payers
• Ensuring Health Technology Assessment readiness
• Securing appropriate coding, coverage, and provider reimbursement at launch
• Leading policy engagement with the current administration

Banko's previous experience includes roles at Cordis Corp (former Johnson & Johnson company) and B. Braun Medical Inc., where he successfully shaped Medicare's national coverage policies and developed strategic global pricing initiatives.

Tevogen Bio (TVGN) has filed a new patent with the USPTO for an innovative T cell vaccine under development. Unlike traditional vaccines focusing on B cell response, this vaccine aims to stimulate T cell responses targeting the entire viral genome, similar to their lead product TVGN 489. The approach is designed to combat mutation risks by targeting multiple viral segments.

The vaccine development is powered by Tevogen.AI's PredicTcell technology for peptide identification. Initially focused on national security and U.S. military biological threat protection, the vaccine's application could be expanded based on needs. The development aligns with Tevogen's previously announced topline forecasts of $1 billion each for their Oncology and Specialty Care divisions.